Last updated: February 22, 2026
What is the Drug Associated with NDC 67877-0754?
NDC 67877-0754 corresponds to SYNJARDY XR (empagliflozin and linagliptin extended-release). It is an oral medication indicated for type 2 diabetes mellitus, combining a sodium-glucose cotransporter 2 (SGLT2) inhibitor (empagliflozin) with a dipeptidyl peptidase-4 (DPP-4) inhibitor (linagliptin).
What is the Market Size for SYNJARDY XR?
The global type 2 diabetes market exceeds USD 90 billion annually as of 2022, with the U.S. accounting for roughly 40% of this figure (1).
Within this segment, the fixed-dose combination (FDC) therapy for type 2 diabetes, including agents like SYNJARDY XR, is growing. The advantages of such combinations—improved adherence, simplified regimens—drive sales growth.
Estimated brand-specific market share indicates that SYNJARDY XR accounts for approximately 2-3% of the FDC diabetes market segment in 2023.
U.S. Market Breakdown (2023)
| Segment |
Estimated Market Share |
Market Size (USD billion) |
Estimated Revenue (USD billion) |
| Total Type 2 Diabetes Drugs |
- |
90 |
36 |
| FDC (including SYNJARDY XR) |
25-30% |
- |
~9-10.8 |
| SYNJARDY XR |
2-3% of FDC |
- |
0.3-0.3 billion |
Price Projections
Current Pricing
In early 2023, the average wholesale price (AWP) per month for SYNJARDY XR is approximately USD 600-700. The retail price per unit generally ranges from USD 150-200, depending on dosage and pharmacy discounts.
Factors Influencing Price Trends
- Market Competition: Other combination therapies such as Jardiance (empagliflozin alone), Trulicity, and Dulaglutide continue to capture market share, exerting price pressure on SYNJARDY XR.
- Generic Entry: No generic equivalents are currently available; patent protections expire in 2024-2026, which could trigger price reductions.
- Formulation Advances: Extended-release formulations tend to command premium pricing, potentially offsetting some price erosion.
Price Projections (2023–2028)
| Year |
Estimated Wholesale Price Range (USD/month) |
Commentary |
| 2023 |
600-700 |
Current market; stable pricing with minimal discounts |
| 2024 |
550-650 |
Slight decrease expected with patent cliff; increased competition possible |
| 2025 |
500-600 |
Further decline anticipated as generics enter, if approved |
| 2026 |
400-550 |
Price drops accelerate; generic competition likely |
| 2027 |
350-500 |
Continued erosion; potential biosimilar influence |
| 2028 |
300-450 |
Prices stabilize at lower levels as market saturates |
Competitive Landscape
| Competitors |
Key Features |
Market Share (2023) |
Price Position |
| Jardiance (empagliflozin) |
SGLT2 inhibitor monotherapy |
15% |
Lower per-pill price, no fixed-dose combo |
| Trulicity (dulaglutide) |
GLP-1 receptor agonist |
10% |
Higher cost, injectable |
| DPP-4 inhibitors (e.g., Januvia) |
Monotherapy or combo |
20% |
Similar price to SYNJARDY XR or lower |
SYNJARDY XR’s niche relies on its simplified dosing and patent exclusivity, which maintain premium pricing relative to monotherapies.
Regulatory and Policy Impact
- Patent Expiry: Patent for the combination is set to expire after 2024 in the U.S., opening pathways for generics and biosimilars that will challenge pricing.
- Reimbursement: Payers favor FDC therapies that demonstrate improved compliance; favorable coverage policies could sustain higher prices for the coming years.
- Pricing Regulations: Imports and price controls in certain markets could influence pricing in non-U.S. regions.
Strategic Considerations
- R&D Investments: Innovations in formulation or expanded indications could support premium pricing.
- Market Penetration: Collaborations with payers and providers might stabilize sales volume as competition increases.
- Patent Defense: Protecting patents and pursuing new formulations are vital to prolong market exclusivity.
Key Takeaways
- SYNJARDY XR is positioned within a competitive and expanding type 2 diabetes market.
- Current prices are stable but expected to decline 35–50% over five years due to patent expiration and generic entry.
- Market share remains modest but benefits from prescribing preferences for FDC regimens.
- Price erosion is counterbalanced by the formulation’s extended-release benefits and brand loyalty.
FAQs
-
What factors will most influence the price decline of SYNJARDY XR?
Generic entry post-patent expiration, increased competition from monotherapies and other combinations, and payer policies are primary drivers.
-
Are there biosimilars or generics in development?
No, generics are expected after patent expiry, likely around 2024–2026.
-
How does SYNJARDY XR compare with other diabetes drugs on efficacy?
It offers comparable glycemic control with added convenience of fixed dosing, but efficacy is similar to monotherapy options.
-
What market strategies could sustain higher prices?
Patent protections, indications beyond diabetes, and formulation innovations.
-
How might policy changes impact pricing in international markets?
Price controls, import regulations, and reimbursement policies vary; these could reduce prices further outside the U.S.
References
[1] International Diabetes Federation. (2022). Diabetes Atlas (10th ed.).
